Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4724 ARTÍCULOS , VIENDO DEL 3031 AL 3045

Type 2 Diabetes Presenting With Persistent Chorea

Chalia M, Subramanian T.

JAMA Neurol. 2019 Mar 1;76(3):366-367. doi: 10.1001/jamaneurol.2018.4089.

Longitudinal assessment of the Unified Huntington's Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington's disease

Winder JY, Achterberg WP, Gardiner SL, Roos RAC.

Eur J Neurol. 2019 May;26(5):780-785. doi: 10.1111/ene.13889. Epub 2019 Jan 27.

Huntington's disease with comorbid myasthenia gravis: a case report

Chatzikonstantinou S, Dagklis I, Kazis D, Karantali E, Bostantjopoulou S.

Hippokratia. 2019 Jan-Mar;23(1):28-29.

The Emerging Roles of Ferroptosis in Huntington's Disease

Mi Y, Gao X, Xu H, Cui Y, Zhang Y, Gou X.

Neuromolecular Med. 2019 Jun;21(2):110-119. doi: 10.1007/s12017-018-8518-6. Epub 2019 Jan 2.

The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer's Disease and Other Neurodegenerative Disorders

Czubowicz K, Jęśko H, Wencel P, Lukiw WJ, Strosznajder RP.

Mol Neurobiol. 2019 Aug;56(8):5436-5455. doi: 10.1007/s12035-018-1448-3. Epub 2019 Jan 5.

A review for the pharmacological effect of lycopene in central nervous system disorders

Chen D, Huang C, Chen Z.

Biomed Pharmacother. 2019 Mar;111:791-801. doi: 10.1016/j.biopha.2018.12.151. Epub 2019 Jan 4.

Pathological role of apoptosis signal-regulating kinase 1 in human diseases and its potential as a therapeutic target for cognitive disorders

Cheon SY, Cho KJ.

J Mol Med (Berl). 2019 Feb;97(2):153-161. doi: 10.1007/s00109-018-01739-9. Epub 2019 Jan 7.

New findings showing how DNA methylation influences diseases

Sallustio F, Gesualdo L, Gallone A.

World J Biol Chem. 2019 Jan 7;10(1):1-6. doi: 10.4331/wjbc.v10.i1.1.

Deutetrabenazine in the treatment of Huntington's disease

Richard A, Frank S.

Neurodegener Dis Manag. 2019 Feb;9(1):31-37. doi: 10.2217/nmt-2018-0040. Epub 2019 Jan 9.

Protective Effects of Antioxidants in Huntington's Disease: an Extensive Review

Essa MM, Moghadas M, Ba-Omar T, Walid Qoronfleh M, Guillemin GJ, Manivasagam T, Justin-Thenmozhi A, Ray B, Bhat A, Chidambaram SB, Fernandes AJ, Song BJ, Akbar M.

Neurotox Res. 2019 Apr;35(3):739-774. doi: 10.1007/s12640-018-9989-9. Epub 2019 Jan 11.

Neuroacanthocytosis with unusual clinical features: A case report

Zhu H, Feng XM, Zhao T, Liu JY.

Medicine (Baltimore). 2019 Jan;98(2):e14050. doi: 10.1097/MD.0000000000014050.

Disease-Modification in Huntington's Disease: Moving Away from a Single-Target Approach

Jensen MP, Barker RA.

J Huntingtons Dis. 2019;8(1):9-22. doi: 10.3233/JHD-180320.

Sample enrichment for clinical trials to show delay of onset in huntington disease

Paulsen JS, Lourens S, Kieburtz K, Zhang Y.

Mov Disord. 2019 Feb;34(2):274-280. doi: 10.1002/mds.27595. Epub 2019 Jan 14.

Behavioral Experimental Paradigms for the Evaluation of Drug's Influence on Cognitive Functions: Interpretation of Associative, Spatial/Nonspatial and Working Memory

Zameer S, Akhtar M, Vohora D.

CNS Neurol Disord Drug Targets. 2019;18(3):185-204. doi: 10.2174/1871527318666190112143834.

SQSTM1/p62: A Potential Target for Neurodegenerative Disease

Ma S, Attarwala IY, Xie XQ.

ACS Chem Neurosci. 2019 May 15;10(5):2094-2114. doi: 10.1021/acschemneuro.8b00516. Epub 2019 Apr 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias